Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hunan Warrant Pharmaceutical Co EV-to-EBITDA?
Hunan Warrant Pharmaceutical CoSHSE:688799 -2.42%83 EV-to-EBITDA is 29.26 as of Sep. 09, 2026, which is 78% above its 10-year median of 16.40. GuruFocus rates SHSE:688799 with a GF Score™ of 83/100 and a GF Value™ of ¥34.70 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 726 Drug Manufacturers companies, Hunan Warrant Pharmaceutical Co ranks worse than 77.96% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hunan Warrant Pharmaceutical Co's enterprise value is ¥7,115 Mil.
Hunan Warrant Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥243 Mil. Therefore, Hunan Warrant Pharmaceutical Co's EV-to-EBITDA for today is 29.26.
The historical rank and industry rank for Hunan Warrant Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
SHSE:688799'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.38 Med: 16.4 Max: 76.78
Current: 28.35
During the past 12 years, the highest EV-to-EBITDA of Hunan Warrant Pharmaceutical Co was 76.78. The lowest was 11.38. And the median was 16.40.
SHSE:688799's EV-to-EBITDA is ranked worse than 77.96% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.4
vs SHSE:688799: 28.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hunan Warrant Pharmaceutical Co (SHSE:688799) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hunan Warrant Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Hunan Warrant Pharmaceutical Co's share price for today is ¥48.41.
Hunan Warrant Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Warrant Pharmaceutical Co EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Warrant Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Warrant Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Warrant Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hunan Warrant Pharmaceutical Co's EV-to-EBITDA falls into.
Hunan Warrant Pharmaceutical Co's current Enterprise Value is ¥7,115 Mil.
Hunan Warrant Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥243 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Warrant Pharmaceutical Co (SHSE:688799) has a EV-to-EBITDA of 29.26 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hunan Warrant Pharmaceutical Co. This is 78% above median its historical median of 16.40. Over the past decade, Hunan Warrant Pharmaceutical Co's EV-to-EBITDA has ranged from 11.38 to 76.78. According to the industry distribution chart, Hunan Warrant Pharmaceutical Co ranks #566 out of 726 companies in the Drug Manufacturers industry, placing it in the top 78%.
Is Hunan Warrant Pharmaceutical Co's EV-to-EBITDA too high?
Hunan Warrant Pharmaceutical Co's current EV-to-EBITDA of 29.26 is 78% above median its 10-year median of 16.40. Over the past 10 years, this metric has ranged from a low of 11.38 to a high of 76.78. The Drug Manufacturers industry median EV-to-EBITDA is 13.40. Hunan Warrant Pharmaceutical Co's value of 29.26 is 118.4% above this industry median. Based on the distribution chart, Hunan Warrant Pharmaceutical Co ranks #566 out of 726 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hunan Warrant Pharmaceutical Co has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Warrant Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hunan Warrant Pharmaceutical Co ranks #566 out of 726 companies for EV-to-EBITDA. This places Hunan Warrant Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.40. Hunan Warrant Pharmaceutical Co's value of 29.26 is 118.4% above this benchmark. Historically, Hunan Warrant Pharmaceutical Co's own EV-to-EBITDA has ranged from 11.38 to 76.78 over the past decade. While the company's 10-year median is 16.40 vs. the industry median of 13.40, Hunan Warrant Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.40, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hunan Warrant Pharmaceutical Co's current EV-to-EBITDA of 29.26 is 118.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hunan Warrant Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Warrant Pharmaceutical Co's current EV-to-EBITDA is 29.26, which is 78% above median its own 10-year median of 16.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Warrant Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co (SHSE:688799) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥34.70, compared to a current price of ¥48.41 — trading 39.5% above its estimated fair value. The current EV-to-EBITDA is 29.26, which is 78% above median its 10-year median of 16.40 and 118.4% above the Drug Manufacturers industry median of 13.40. Hunan Warrant Pharmaceutical Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hunan Warrant Pharmaceutical Co (SHSE:688799), the current EV-to-EBITDA is 29.26 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Warrant Pharmaceutical Co (SHSE:688799) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥48.41 is trading 39.5% above its estimated GF Value™ of ¥34.70.
GuruFocus considers Hunan Warrant Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:688799:
EV-to-EBITDA: 29.26 (78% above median its 10-year median of 16.40)
GF Value™: ¥34.70 vs. price of ¥48.41 (39.5% above fair value)
Industry Position: 118.4% above the Drug Manufacturers median (#566 of 726)
No single metric tells the full story. See the SHSE:688799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Warrant Pharmaceutical Co Ltd is a pharmaceutical manufacturer. It is engaged in the research and development, production and sales of chemical raw materials, chemical medicine preparations and Chinese medicine preparations.
83GF Score
Get the complete analysis for SHSE:688799
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688799 has been successfully added to your 
